Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

85.23 -3.61 (-4.06%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist

Price and Volume

Volume	105,830
Open	89.58
Bid (Size)	73.78 (100)
Ask (Size)	111.00 (100)
Prev. Close	88.84
Today's Range	85.06 - 90.00
52wk Range	50.07 - 124.82
Shares Outstanding	14,157,941
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

August 19, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 12, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	+29.1%	+29.1%
1 Month	-25.0%	-25.0%
3 Month	-2.8%	-2.8%
6 Month	+57.6%	+57.6%
1 Year	+10.1%	+10.1%

More News

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

July 22, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

July 20, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

June 30, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

June 26, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

June 01, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

May 19, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 14, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

April 19, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

March 27, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

March 02, 2026

From Monopar Therapeutics Inc.

Via GlobeNewswire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

November 14, 2025

Via Benzinga

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

November 13, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

November 09, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

October 15, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

October 13, 2025

Via Benzinga

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 25, 2025

Via Benzinga

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

September 23, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

September 23, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout ↗

September 15, 2025

Via Investor's Business Daily

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

September 03, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

September 14, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

August 12, 2025

From Monopar Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Monopar Therapeutics Inc. - Common Stock publicly traded?

Yes, Monopar Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Monopar Therapeutics Inc. - Common Stock trade on?

Monopar Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Monopar Therapeutics Inc. - Common Stock?

The ticker symbol for Monopar Therapeutics Inc. - Common Stock is MNPR on the Nasdaq Stock Market

What is the current price of Monopar Therapeutics Inc. - Common Stock?

The current price of Monopar Therapeutics Inc. - Common Stock is 85.23

When was Monopar Therapeutics Inc. - Common Stock last traded?

The last trade of Monopar Therapeutics Inc. - Common Stock was at 09/25/26 04:00 PM ET

What is the market capitalization of Monopar Therapeutics Inc. - Common Stock?

The market capitalization of Monopar Therapeutics Inc. - Common Stock is 1.21B

How many shares of Monopar Therapeutics Inc. - Common Stock are outstanding?

Monopar Therapeutics Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.